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Thrombolytic therapy for acute ischaemic stroke: 
is the hype justified?
L E T T E R  T O
T H E  E D I T O R
References
1.	 Lau	AY,	Soo	YO,	Graham	CA,	et	al.	An	expedited	 stroke	 triage	pathway:	 the	key	 to	 shortening	 the	door-to-needle	 time	 in	
delivery	of	thrombolysis.	Hong	Kong	Med	J	2010;16:455-62.	
2.	 Tissue	plasminogen	activator	 for	 acute	 ischemic	 stroke.	The	National	 Institute	of	Neurological	Disorders	 and	Stroke	 rt-PA	
Stroke	Study	Group.	N	Engl	J	Med	1995;333:1581-7.	
3.	 Kumana	CR.	Déja	Vu.	JAMA	Southeast	Asian	Edition	1999;15:5-6. 
4.	 Kumana	CR,	Cheung	BM.	Thrombolysis	for	ischaemic	stroke.	Clin	Med	2008;8:556.	
To the Editor—Implementation of thrombolytic 
therapy for acute ischaemic stroke1 has to be viewed 
in an appropriate context.
 The main justification for such therapy relies 
on findings from a relatively small, randomised 
controlled trial known by the acronym NINDS 
(National Institute of Neurological Disorders and 
Stroke rt-PA trial),2 about which there are serious 
reservations.3 Overall treatment benefits (if any) 
were trivial, whilst there were very high risks of 
adverse events such as intracranial haemorrhage, and 
immense logistical and financial implications. This 
was in marked contrast to the very favourable benefits 
of thrombolysis for acute myocardial infarction. 
 Moreover, in two particularly important 
respects, the NINDS trial can be regarded as flawed.4 
First, part 2 of the trial (the main impetus for this 
treatment) relied on a global test statistic as the 
primary outcome, and not on incontrovertible hard 
endpoints. The latter arbitrary statistic was itself 
a composite of four neurological scores (Table). 
Clinically and statistically significant differences 
depending on any such composite of inter-related 
overlapping soft endpoints must be inherently 
suspected. Second, patients in both the control and 
active treatment groups received no aspirin in the 
first 24 hours, so that those treated with recombinant 
tissue plasminogen activator (t-PA) were compared 
with controls who received suboptimal standard 
therapy. To overcome the risk of serious intracranial 
bleeding from combined t-PA plus aspirin therapy, 
dummy aspirin should have been administered to 
the active treatment group and genuine aspirin to the 
controls.
 Under these circumstances, is the hype 
surrounding this form of treatment for acute 
ischaemic stroke appropriate and justified?
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* RR denotes relative risk, and CI confidence interval
† NNT = number needed to treat to attain a favourable outcome (for a once-off intervention)
‡ For the Global Statistic, a favourable odds ratio and 95% CI were reported (1.7 [1.2 to 2.6]) but how they were derived was not detailed; 
whilst individually, only when adjusted did its component scores attain statistical significance. BI denotes Barthel Index, MRS modified 
Rankin Score, GCS Glasgow Coma Scale, and NIHSS National Institute of Health Stroke Score
§ NNH = number needed to harm is inferred when the number needed to treat is negative
TABLE.  Unadjusted relative risk and number needed to treat values derived from published National Institute of Neurological 
Disorders and Stroke rt-PA trial data2
Outcome at 3 months RR (95% CI)* NNT† (95% CI)
Composite Global Statistic Components‡ Favourable BI 1.3 (0.8 to 2.0) 15 (-34 to 6)
Favourable MRS 1.5 (0.9 to 2.4) 13 (-84 to 6)
Favourable GCS 1.4 (0.8 to 2.1) 15 (-42 to 6)
Favourable NIHSS 1.5 (0.9 to 2.7) 16 (-66 to 6)
Symptomatic or fatal intracranial haemorrhage 
within 36 hours of treatment
5.9
(1.3 to 27.1)
NNH§ 17
(10 to 62)
